Aprea Therapeutics, Inc. (APRE) Stock Price, Financials & Summary

Price chart

Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29

Key dataOct 29, 2026

Open$0.51

From 52W high−65.96%

Volume171488.00

Market cap$6.21M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 29, 2026

Open

$0.51

From 52W high

−65.96%

Volume

171488.00

Market cap

$6.21M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

2.9x

P/E (TTM)

—

RSI (14)

37.1

MomentumView details →

1D Return

−8.22%

YTD Return

−42.05%

SummaryUpdated Jun 1, 2026

Aprea Therapeutics, Inc. (NASDAQ:APRE) is a clinical-stage biopharmaceutical company founded in 2002 and based in Boston, Massachusetts. The company went public in October 2019 and focuses on developing novel cancer therapeutics that target DNA damage response pathways. Aprea operates as a small biotechnology firm dedicated to advancing innovative treatments for patients with advanced solid tumors through its pipeline of experimental drugs currently in various stages of clinical development.

Ask drillr about Aprea Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

2.9x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−31.99%

ROA (TTM)

−29.10%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+53.45%

FCF YoY

+4.38%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

+17.87%

EBITDA YoY

+15.12%

MomentumView details →

1D Return

−8.22%

YTD Return

−42.05%

1Y Return

−65.91%

RSI (14)

37.1

vs 50D SMA

−29.33%

vs 200D SMA

−34.54%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

13.55x

Quick Ratio

13.55x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.07

EPS Surprise

60.56%

Beats (12Q)

10/12

Next Q EPS Est

−$0.08

Avg Surprise (4Q)

−61.10%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−12.31M

Op. CF (TTM)

−12.17M

Next earningsNov 11, 2026 →

Latest newsMore news →

Aprea Therapeutics announced that it will host a virtual panel discussion on WEE1 inhibition in precision oncology on October 20, 2026, at 11 a.m. ET.13d ago

Aprea Therapeutics announced its financial results for the second quarter of 2026.78d ago

Similar companies

Exicure, Inc.XCUR Evogene Ltd.EVGN Enveric Biosciences, Inc.ENVB Senti Biosciences, Inc.SNTI Alzamend Neuro, Inc.ALZN FibroBiologics, Inc. Common StockFBLG Find similar companies →

Latest newsMore news →

Aprea Therapeutics announced that it will host a virtual panel discussion on WEE1 inhibition in precision oncology on October 20, 2026, at 11 a.m. ET.13d ago Aprea Therapeutics announced its financial results for the second quarter of 2026.78d ago